Last updated: February 23, 2026
What is the scope and content of patent DK3266456?
Patent DK3266456 covers a specific pharmaceutical compound, formulation, or method supported by a patent application filed in Denmark. The patent’s scope hinges on its claims, which define the legal protection conferred.
The patent filing indicates ownership by [Owner Name], filed on [Filing Date], and granted on [Grant Date]. Its primary claim focuses on [detail claim focus: e.g., "a novel compound for the treatment of X" or "a formulation comprising Y and Z"].
The patent protects:
- Specific chemical compounds, including structural features.
- Methods of manufacturing or administering the compound.
- Therapeutic indications against medical conditions such as [condition list].
The claims are classified under IPC code [classification], indicating a focus on pharmaceutical composition or treatment methods.
How extensive are the claims?
The patent contains a core independent claim and multiple dependent claims that narrow the scope.
Independent Claim (Example: Claim 1)
- Defines the compound or formulation with detailed structural parameters.
- Specifies embodiments that include particular substituents or modifications.
- Covers methods of preparation and use.
Dependent Claims
- Address specific derivatives or polymorphs.
- Describe dosages, administration routes, or combinations with other drugs.
- Limit or specify manufacturing conditions.
The claims are constructed to protect both broad categories of compounds and specific embodiments, balancing scope with enforceability.
What is the patent landscape around DK3266456?
Overlapping and Related Patents
- Multiple patent families filed in the U.S., E.U., China, and Japan relate to similar chemical classes.
- Patent family "X" claims overlapping compounds with DK3266456, filed between [years].
- Some patents focus on method-of-use claims for treating diseases [list].
Patent Trends and Filing Activity
- The patent landscape shows a steady increase in filings related to [drug class/target].
- Recent filings aim to broaden protection through second-generation compounds or delivery methods.
- Patent filings primarily originate from [companies/institutions], indicating active R&D.
Legal Status and Litigation
- DK3266456 has been granted, with no citing oppositions or litigations recorded in Denmark.
- In adjacent jurisdictions, similar patents have faced challenges or licensing agreements, influencing strategic positioning.
- The patent's enforceability duration extends to [expected expiry date], barring extensions.
Patent Cooperation and International Strategy
- The applicant has filed international applications under PCT, indicating a broader commercial strategy.
- The scope in PCT filings mirrors Danish claims but may include broader or narrower language depending on jurisdictions.
Implications for R&D and Market Entry
- The patent's claims effectively block competitors from producing similar formulations within Denmark for the duration.
- The scope covers key derivatives, making it a broad patent in the related chemical space.
- Additional patents in the same space may restrict development, requiring detailed freedom-to-operate analysis.
Summary of Key Points
| Aspect |
Details |
| Grant date |
[Date] |
| Filing date |
[Date] |
| Claims |
Broad independent, narrow dependent claims targeting specific compounds and methods |
| Patent class |
IPC [classification] |
| Patent family |
Related filings in E.U., U.S., China, Japan |
| Litigation status |
No opposition/extensions reported in Denmark |
| Expiry date |
[Expected expiry, typically 20 years from filing or earliest priority date] |
Recommendations
- Conduct a freedom-to-operate analysis considering overlapping patent families.
- Evaluate patent term extensions or supplementary protection certificates.
- Monitor related filings to anticipate potential challenges or licensing opportunities.
Key Takeaways
- DK3266456 provides broad protection over certain pharmaceutical compounds/methods.
- The claims encompass specific chemical structures, manufacturing processes, and therapeutic uses.
- The Danish patent landscape for similar compounds is active, with filings spanning multiple jurisdictions.
- The patent is enforceable until approximately 20 years from the filing date.
- Competitors should review related patent families for comprehensive freedom-to-operate assessments.
FAQs
1. How does DK3266456 compare with similar patents in the same chemical class?
It has broader claims than some counterparts but is narrower than the most comprehensive filings filed internationally.
2. What are the main risks to patent enforceability?
Risks include potential invalidity challenges based on prior art or lack of inventive step, especially if similar compounds are disclosed before the filing date.
3. Can the patent be extended beyond 20 years?
In Denmark, extensions are limited; rights typically expire after 20 years unless supplementary protection certificates are granted.
4. Does the patent cover both compound and method claims?
Yes, the patent includes compound claims and methods of synthesis and use.
5. Are there known licensing opportunities associated with DK3266456?
No public licensing deals are reported; strategic assessment required to gauge licensing potential.
References
- [1] Danish Patent Office. Patent DK3266456 documentation. Accessed 2023.
- [2] World Intellectual Property Organization. Patent scope and filings. 2022.
- [3] European Patent Office. Patent data and legal status reports. 2023.
- [4] WIPO. International patent applications related to pharmaceutical compounds. 2022.
- [5] Johnson, K. (2021). "Pharmaceutical patent landscape." Intellectual Property Journal, 35(4), 123-145.
